H. pylori (Helicobacter pylori)

1. Overview
2. Epidemiology
3. Pathophysiology
4. Diseases Caused
5. Diagnosis
6. Treatment (Eradication)
7. Eradication and Cancer Prevention
8. Research Papers
9. Connections

Overview

Helicobacter pylori (H. pylori) is a gram-negative, spiral-shaped bacterium that colonizes the gastric mucosa of the human stomach. It is the most common chronic bacterial infection worldwide, affecting approximately 50% of the global population — and substantially more in developing nations.

The bacterium preferentially colonizes the gastric antrum, the lower portion of the stomach closest to the pylorus. Its remarkable ability to survive in the acidic gastric environment depends on a key virulence tool: the enzyme urease. Urease splits urea into ammonia and carbon dioxide; the ammonia neutralizes stomach acid immediately surrounding the bacterium, creating a micro-environment where H. pylori can thrive.

Two additional virulence factors define its pathogenic power:

• CagA (cytotoxin-associated gene A) — present in roughly 60–70% of Western strains and nearly all East Asian strains. CagA is injected directly into gastric epithelial cells via a type IV secretion system (essentially a molecular syringe). Inside the cell, CagA disrupts tight junctions, disturbs cell polarity, and activates oncogenic signaling cascades — contributing directly to cancer risk.
• VacA (vacuolating cytotoxin A) — a pore-forming toxin that inserts into cell membranes, induces vacuolation of the cytoplasm, damages mitochondria, and triggers apoptosis (programmed cell death). VacA also suppresses local immune responses, helping the bacterium persist for decades.

H. pylori was discovered in 1982 by Barry Marshall and Robin Warren, who were awarded the Nobel Prize in Physiology or Medicine in 2005. Their discovery overturned the prevailing belief that ulcers were caused by stress and acid alone, revealing instead that a curable bacterial infection was responsible for the majority of peptic ulcers worldwide.

Back to Table of Contents

Epidemiology

H. pylori infects an estimated 4.4 billion people globally — roughly half of all living humans. Infection rates vary dramatically by geography and socioeconomic conditions:

• Developing countries: prevalence ranges from 70–80%, reflecting overcrowded living conditions, limited access to clean water, and inadequate sanitation.
• Developed countries: prevalence of 30–40%, with rates declining in younger generations due to improved hygiene and antibiotic use.
• Highest prevalence regions: Sub-Saharan Africa (>70%), South America, Southeast Asia, and Eastern Europe.
• Lowest prevalence regions: Western Europe, Australia, Canada, and the United States (where it has fallen to roughly 30–35%).

Transmission occurs primarily via two routes:

• Fecal-oral: contaminated water or food, particularly in areas without reliable sewage treatment.
• Oral-oral: shared utensils, kissing, and possibly through saliva — explaining intrafamilial clustering.

Infection is acquired predominantly in childhood, often before age 5. Once established, it persists for life without treatment. Spontaneous clearance is rare.

The public health stakes are enormous. H. pylori is classified as a Group 1 carcinogen by the International Agency for Research on Cancer (IARC). H. pylori-related gastric cancer kills approximately 700,000 people per year worldwide, making it one of the most deadly infectious causes of cancer. Gastric cancer remains the fifth most common cancer and fourth leading cause of cancer death globally.

Back to Table of Contents

Pathophysiology

H. pylori's persistence and pathogenicity stem from a sophisticated series of interactions with the gastric mucosa that, over years to decades, drive a predictable cascade of tissue damage:

Initial Colonization

After ingestion, H. pylori uses its flagella to swim through the gastric mucus layer toward the epithelial surface. Urease production begins immediately — ammonia neutralizes local pH, making the bacterium's immediate micro-environment survivable. Adhesins on the bacterial surface bind to specific receptors on gastric epithelial cells, securing attachment.

CagA Injection and Oncogenic Signaling

CagA-positive strains (cagPAI — cag pathogenicity island) assemble a type IV secretion system that functions like a molecular needle, injecting the CagA protein directly into epithelial cells. Once inside:

• CagA is phosphorylated by Src kinases, then activates SHP-2 phosphatase — a known proto-oncogene.
• It disrupts the E-cadherin/beta-catenin complex, impairing epithelial tight junctions and cell polarity.
• It activates NF-κB, driving inflammatory cytokine production (IL-8 in particular), which recruits neutrophils and macrophages.
• Persistent CagA signaling mimics growth-factor stimulation, promoting aberrant proliferation.

VacA-Mediated Cell Injury

VacA is secreted by virtually all H. pylori strains, though toxin activity varies by allele. VacA inserts into mitochondrial and plasma membranes, forming anion-selective channels. The downstream effects include:

• Large vacuole formation in the cytoplasm (the hallmark the toxin is named for).
• Mitochondrial fragmentation and dysfunction, releasing cytochrome c and triggering apoptosis.
• Inhibition of T-cell proliferation and IL-2 secretion — local immune evasion.

The Correa Cascade (Gastric Carcinogenesis)

Decades of chronic active gastritis, driven by CagA, VacA, and the persistent inflammatory response, set in motion a stepwise progression described by Pelayo Correa:

1. Normal gastric mucosa
2. Chronic non-atrophic gastritis
3. Atrophic gastritis (loss of parietal cells and acid-producing glands)
4. Intestinal metaplasia (gastric epithelium replaced by intestinal-type cells)
5. Dysplasia
6. Gastric adenocarcinoma

This progression unfolds over 20–40 years. Eradication early in the cascade (before intestinal metaplasia) dramatically reduces cancer risk; eradication after intestinal metaplasia has developed still reduces risk but does not fully reverse it.

Back to Table of Contents

Diseases Caused

H. pylori infection causes or strongly contributes to several distinct gastrointestinal diseases:

Peptic Ulcer Disease

H. pylori is responsible for approximately 95% of duodenal ulcers and 70% of gastric ulcers in the absence of NSAID use. The bacterium disrupts the balance between acid secretion and mucosal defense: in the duodenum, H. pylori-driven antral gastritis increases gastrin production → increased acid output → acid overwhelms duodenal defenses. In the stomach, direct mucosal injury and impaired prostaglandin synthesis reduce the mucus barrier. Eradication of H. pylori heals ulcers and, critically, prevents recurrence — transforming peptic ulcer disease from a chronic relapsing condition into a curable one.

Gastric Adenocarcinoma

H. pylori is the single most important risk factor for gastric cancer, accounting for roughly 75–89% of all non-cardia gastric adenocarcinomas. IARC classifies H. pylori as a Group 1 carcinogen. The estimated lifetime risk of developing gastric cancer in an infected individual is approximately 1–3% in Western populations and up to 6% in high-incidence regions (East Asia). Gastric cancer remains a leading cancer killer globally, killing approximately 769,000 people per year.

MALT Lymphoma

Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach is directly driven by chronic H. pylori antigen stimulation of gastric B cells. In approximately 75% of low-grade cases, antibiotic eradication of H. pylori alone — without chemotherapy or radiation — causes complete lymphoma remission. This represents one of the most dramatic examples of infectious disease treatment curing a cancer. High-grade (large B-cell) gastric lymphomas also benefit from eradication as part of combined treatment.

Functional Dyspepsia

H. pylori infection is present in roughly 50% of patients with functional dyspepsia (chronic upper abdominal pain or discomfort without organic cause on endoscopy). A modest but real proportion of these patients — roughly 1 in 10 — experience long-term symptom relief with eradication. Current guidelines therefore recommend a test-and-treat strategy for uninvestigated dyspepsia under age 60 without alarm features.

Protective Associations (the H. pylori Paradox)

In an intriguing counterpoint, H. pylori infection is inversely associated with:

• Gastroesophageal reflux disease (GERD): H. pylori, particularly CagA-positive strains, appears to suppress acid output in the esophageal-junction region. Eradication can unmask or worsen GERD in some patients — a clinical consideration before treating patients who have both H. pylori and mild reflux.
• Esophageal adenocarcinoma: paralleling the GERD relationship, populations with lower H. pylori prevalence have higher rates of esophageal adenocarcinoma.
• Asthma and allergies: consistent with the hygiene hypothesis, early H. pylori colonization may modulate immune development in ways that reduce atopic disease risk.

Back to Table of Contents

Diagnosis

The appropriate diagnostic approach depends on clinical context — specifically whether the patient needs endoscopy for other reasons (alarm features) or can be managed non-invasively.

Test-and-Treat Strategy

For patients under age 60 with uninvestigated dyspepsia and no alarm features, current ACG, AGA, and ACG-CAG guidelines recommend a test-and-treat strategy: non-invasively test for H. pylori, treat if positive, and reserve endoscopy for those who don't improve. This approach is cost-effective and avoids unnecessary procedures.

Non-Invasive Tests

Urea Breath Test (UBT) — Gold Standard Non-Invasive Test

The patient swallows a capsule or solution containing ¹³C-labeled urea. If H. pylori is present, its urease enzyme splits the labeled urea, releasing ¹³CO₂ that is absorbed into the bloodstream and exhaled. Breath is collected and analyzed for the isotopic signature. Sensitivity and specificity both exceed 95%. Key requirements:

• Stop proton pump inhibitors (PPIs) at least 2 weeks before testing (PPIs suppress H. pylori activity and cause false negatives).
• Stop antibiotics and bismuth at least 4 weeks before testing.

Stool Antigen Test (HpSA)

Detects H. pylori antigens in a stool sample. Monoclonal antibody-based assays are preferred (sensitivity and specificity >95%). Inexpensive and widely available. Subject to the same PPI/antibiotic restriction as UBT. Useful for both initial diagnosis and confirming eradication.

Serology (IgG antibody test)

Detects IgG antibodies against H. pylori in blood. Widely available and inexpensive, but with a critical limitation: antibodies persist for months to years after successful eradication. Serology cannot distinguish active from past infection and therefore cannot be used to confirm eradication. Its use is increasingly discouraged for clinical decision-making.

Invasive Tests (Endoscopy + Biopsy)

When endoscopy is performed for clinical indications, several H. pylori tests can be performed on biopsy specimens:

• Rapid urease test (CLOtest): biopsy placed in urea-containing medium; color change indicates urease activity. Results within minutes to hours. Sensitivity ~90–95%.
• Histology: H&E or Giemsa staining of antral/body biopsies identifies the organism and grades gastritis. Allows simultaneous assessment of intestinal metaplasia and dysplasia.
• Culture: allows antibiotic susceptibility testing — valuable when standard regimens have failed. Technically demanding and not widely available.

Alarm Features Mandating Endoscopy

The following features require upper endoscopy rather than empiric test-and-treat:

• Age >60 years (new dyspepsia)
• Unintentional weight loss
• Dysphagia or odynophagia
• Gastrointestinal bleeding (hematemesis, melena, hematochezia)
• Iron deficiency anemia
• Palpable abdominal mass
• Family history of gastric cancer
• Prior gastric surgery

Back to Table of Contents

Treatment (Eradication)

Antibiotic resistance has fundamentally changed H. pylori treatment. Clarithromycin resistance now exceeds 15–20% in many parts of the United States, Europe, and East Asia, and metronidazole resistance is even higher globally. Standard triple therapy (PPI + clarithromycin + amoxicillin × 7–10 days) that once achieved >90% cure rates now frequently fails below 80% in high-resistance regions. Current guidelines emphasize resistance-aware regimen selection and 14-day treatment duration.

Bismuth Quadruple Therapy — Preferred First-Line (Most Regions)

The most reliable regimen across diverse resistance landscapes:

• PPI (standard or double dose) twice daily
• Bismuth subcitrate or subsalicylate 120–300 mg four times daily
• Metronidazole 500 mg three to four times daily
• Tetracycline 500 mg four times daily
• Duration: 14 days

Bismuth quadruple therapy achieves eradication rates of approximately 85–90% even in areas with high clarithromycin and metronidazole resistance. It is available as a single capsule (Pylera) containing bismuth, metronidazole, and tetracycline. Side effects include dark stools and tongue (harmless bismuth discoloration), nausea, and diarrhea.

Standard Triple Therapy

• PPI twice daily + clarithromycin 500 mg twice daily + amoxicillin 1 g twice daily × 14 days

Acceptable as first-line only in regions where clarithromycin resistance is confirmed to be below 15% and the individual patient has not previously received a macrolide antibiotic. Eradication rates with 14-day triple therapy are approximately 70–85% even under favorable conditions.

Concomitant (Non-Bismuth Quadruple) Therapy

• PPI + clarithromycin 500 mg + amoxicillin 1 g + metronidazole 500 mg — all twice daily × 14 days

Recommended in areas with dual clarithromycin and metronidazole resistance, or where bismuth is unavailable. Eradication rates of approximately 85–90% in appropriate populations.

Vonoprazan-Based Therapy — FDA-Approved 2022

Vonoprazan is a potassium-competitive acid blocker (P-CAB) — a new class of acid suppressant that provides faster, more complete, and more durable acid suppression than conventional PPIs regardless of CYP2C19 metabolism. FDA-approved regimens:

• Dual therapy: vonoprazan 20 mg twice daily + amoxicillin 1 g three times daily × 14 days (eradication ~84% in clinical trials)
• Triple therapy: vonoprazan 20 mg + amoxicillin 1 g + clarithromycin 500 mg — all twice daily × 14 days (eradication ~79% in clarithromycin-resistant strains)

Vonoprazan-based regimens consistently outperform PPI-based triple therapy in head-to-head trials and are particularly valuable in CYP2C19 rapid metabolizers (who clear PPIs quickly) and in amoxicillin-susceptible strains.

Salvage (Second-Line) and Third-Line Therapy

When first-line therapy fails, regimen choice should ideally be guided by culture and susceptibility testing. If culture is unavailable:

• Levofloxacin-based triple therapy: PPI + levofloxacin 500 mg + amoxicillin 1 g, all twice daily × 14 days — reasonable salvage option where fluoroquinolone resistance is low.
• Rifabutin-based triple therapy: PPI + rifabutin 150 mg + amoxicillin 1 g, twice daily × 14 days — reserved for multidrug-resistant cases. Risk of myelotoxicity limits widespread use.

Confirming Eradication

Eradication must always be confirmed — treatment failure is common and consequences of unrecognized failure (recurrent ulcers, ongoing cancer risk) are serious. Confirm with UBT or monoclonal stool antigen test:

• At least 4 weeks after completing antibiotics
• Off PPIs for at least 2 weeks before testing

Back to Table of Contents

Eradication and Cancer Prevention

One of the most consequential findings in modern gastroenterology is that eradicating H. pylori reduces the subsequent risk of gastric cancer. The evidence is now robust:

• Meta-analyses of randomized controlled trials demonstrate a 40–50% reduction in gastric cancer incidence among infected individuals who receive eradication therapy compared to those who do not.
• The benefit is greatest when eradication occurs before intestinal metaplasia develops — once the mucosa has undergone intestinal metaplasia, cancer risk is reduced but not eliminated by eradication.
• A landmark study from Japan (N Engl J Med, 2001) showed that none of 255 patients with early gastric cancer who received eradication developed metachronous gastric cancer over follow-up, versus 9 of 250 controls.

Population-Level Eradication Programs

Japan and Taiwan have implemented national H. pylori eradication programs, with dramatic results:

• Taiwan's school-age eradication program in Matsu Islands (begun 2004) reduced H. pylori prevalence from 64.2% to 15.0% over 10 years and cut gastric cancer incidence by 53% and peptic ulcer prevalence by 67%.
• Japan's expansion of eradication therapy coverage under national health insurance for all H. pylori-positive gastritis patients (2013) has already reduced endoscopy-detected gastric cancer rates in subsequent years.

WHO Recommendations

The World Health Organization and IARC now recommend screen-and-treat strategies in intermediate- and high-incidence populations (defined as gastric cancer incidence >20 per 100,000 per year). In lower-incidence settings (most of Western Europe, North America), targeted testing of at-risk groups — first-generation immigrants from high-incidence countries, individuals with family history of gastric cancer — is emphasized alongside the standard test-and-treat approach for dyspepsia.

MALT Lymphoma Remission

For the specific case of low-grade gastric MALT lymphoma, H. pylori eradication is first-line treatment — not just an adjunct. Approximately 75% of localized low-grade gastric MALT lymphomas achieve complete remission with antibiotic eradication alone, without any need for radiation or chemotherapy. This remains one of the most compelling examples in oncology of treating an infection to cure a cancer.

Back to Table of Contents

Key Research Papers

1. Malfertheiner P et al. Management of Helicobacter pylori infection — Maastricht IV/Florence Consensus Report. Gut. 2012;61(5):646–664. — Search PubMed
2. Hooi JKY et al. Global prevalence of Helicobacter pylori infection. Gastroenterology. 2017;153(2):420–429. — Search PubMed
3. Graham DY. Helicobacter pylori update. Gastroenterology. 2015;148(4):719–731. — Search PubMed
4. Peek RM Jr, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer. 2002;2(1):28–37. — Search PubMed
5. Chey WD et al. ACG Clinical Guideline: Treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112(2):212–239. PMID 28071659
6. Crowe SE. Helicobacter pylori infection. N Engl J Med. 2019;380(12):1158–1165. PMID 30893536
7. Sugano K et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353–1367. — Search PubMed
8. Ford AC et al. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev. 2016;4:CD003840. — Search PubMed
9. Wroblewski LE et al. Helicobacter pylori and gastric cancer. Front Microbiol. 2010;1:131. — Search PubMed
10. Fallone CA et al. The Toronto Consensus for the Treatment of Helicobacter pylori. Gastroenterology. 2016;151(1):51–69. PMID 27102658
11. Graham DY, Liou JM. Primer for development of guidelines on Helicobacter pylori. Gastroenterology. 2022;163(5):1158–1167. — Search PubMed
12. Schulz C et al. Vonoprazan-based Helicobacter pylori eradication. Aliment Pharmacol Ther. 2022;56(5):768–780. — Search PubMed

Research Papers

Search PubMed for the latest research on these H. pylori topics:

1. H. pylori eradication therapy
2. H. pylori and gastric cancer prevention
3. H. pylori antibiotic resistance
4. Vonoprazan H. pylori treatment
5. H. pylori and MALT lymphoma
6. H. pylori urea breath test diagnosis
7. CagA virulence factor
8. H. pylori and peptic ulcer disease
9. H. pylori global prevalence
10. Bismuth quadruple therapy
11. H. pylori and functional dyspepsia
12. H. pylori screen-and-treat programs

Connections

• Stomach Acid, pH & the PPI Trade-off — interactive animation
• Gastroenterology Hub
• Peptic Ulcer Disease
• Gastritis
• Barrett's Esophagus
• SIBO
• Crohn's Disease
• C. diff (Clostridioides difficile)
• Mastic Gum
• Zinc

Back to Table of Contents

Featured Videos